Cardiorenal Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus With Nephrotic‐Range Proteinuria: A Multi‐Institutional Target Trial Emulation

Key Points

• To evaluate the cardiorenal outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) compared to DPP4 inhibitors in patients with type 2 diabetes and nephrotic-range proteinuria.
• Multi-institutional observational study design
• Comparison of SGLT2i and DPP4i usage
• Assessment of kidney and cardiovascular outcomes over a long-term period
• SGLT2i associated with lower long-term risks of end-stage kidney disease (ESKD) and all-cause mortality
• No significant differences in cardiovascular or safety outcomes between SGLT2i and DPP4i observed

Abstract